« Back
Home /
Tivozanib

Tivozanib

Item no.	HY-10977-25mg
Manufacturer	MedChem Express
CASRN	475108-18-0
Amount	25 mg
Category	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer Colorectal Cancer Breast Cancer
Type	Inhibitors
Specific against	other
Purity	99.80
Citations	[1]Nakamura K, et al., KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 2006 Sep 15;66(18):9134-42.
Smiles	O=C(NC1=CC=C(C=C1Cl)OC2=CC=NC3=CC(OC)=C(C=C23)OC)NC4=NOC(C)=C4
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	AV-951,KRN951
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound1
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - HS Code	H302, H315, H319, H335
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Product Description	Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO : 25 mg/mL (ultrasonic)
Manufacturer - Pathway	Protein Tyrosine Kinase/RTK
Clinical information	Launched
Isoform	VEGFR1/Flt-1; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4
UNSPSC Code	12352005
Precautionary	H302, H315, H319, H335

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.